Roche Hemlibra with 22% US patient share, to update Spark Hemophilia A gene therapy data at ISTH in July 2020, no mention of phase 3 yet, nor any future filing date yet. $BMRN $PFE $SGMO https://t.co/XVXWIyJnK2